
Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Medulloblastoma medical therapy
Introduction
Overview
Overview
Risk stratification determines the protocol of management used for medulloblastoma patients. Radiotherapy is the mainstay of treatment for medulloblastoma. Radiotherapy for medulloblastoma must be started within the 6 weeks period following surgery. Adjunctive chemotherapy is also required for the management of certain medulloblastoma patients. Recommended chemotherapeutic regimens used for the management of standard risk medulloblastoma patients include a combination of lomustine, vincristine, and cisplatin.[1][2]
Medical Therapy
Medical Therapy
 |  |  | Optimal surgical excision |  |  |  | |||||||||||||||||||||||
 |  |  |  |  |  |  |  |  |  |  | |||||||||||||||||||
 |  |  | Histopathological analysis and detailed staging |  |  |  | |||||||||||||||||||||||
 |  |  |  |  |  |  |  |  |  |  | |||||||||||||||||||
 |  |  |  |  |  | ||||||||||||||||||||||||
 |  |  |  |  |  |  |  |  |  |  | |||||||||||||||||||
 |  |  | Radiotherapy and chemotherapy
administered according to the risk stratification criteria | Â | Â | Â | Â | Â | Â | Â | Â | Â | |||||||||||||||||
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | ||||||||||||
 |  |  |  |  |  | ||||||||||||||||||||||||
 | Standard risk patients |  | High risk patients |  |  |  |  |  |  | ||||||||||||||||||||
 |  |
Craniospinal radiation followed by chemotherapy | Â | Â | Â | Â | Â | Â | |||||||||||||||||||||
Risk Stratification
- The table below demonstrates the risk stratification for medulloblastoma patients:
| Parameters | Standard Risk Group | High Risk Group |
|---|---|---|
|
Age |
|
|
|
Extent of previous surgical resection |
|
|
|
Tumor stage |
| |
| Management Protocol | Craniospinal radiation OR Chemoradiotherapy followed by additional chemotherapy |
Craniospinal radiation followed by chemotherapy |
Radiation Therapy
- Radiotherapy is the mainstay of treatment for medulloblastoma.
- Radiotherapy for medulloblastoma must be started within the 6 weeks period following surgery.
- The main radiotherapy techniques used in the management of medulloblastoma patients include:
- Conventional radiotherapy technique
- Intensity modulated radiotherapy technique
- Three dimensional radiotherapy technique
- Three dimensional radiotherapy technique demonstrated better outcomes when compared to conventional and intensity modulated radiotherapy techniques.
- The dose of radiation is adjusted according to the risk stratification of medulloblastoma patients.
- As medulloblastoma tends to spread along the cerebrospinal fluid, it is recommended to deliver a craniospinal irradiation with a boost to the posterior fossa.
- Side effects of radiotherapy may include:
Chemotherapy
- Adjunctive chemotherapy is required for the management of medulloblastoma patients.
- Recommended chemotherapeutic regimens used for the management of standard risk medulloblastoma patients include a combination of lomustine AND vincristine AND cisplatin
- Other chemotheuraptic agents that may be used for the management of high risk medulloblastoma patients include:
References
References
- ↑ 1.0 1.1 1.2 von Hoff K, Rutkowski S (2012). “Medulloblastoma”. Curr Treat Options Neurol. 14 (4): 416–26. doi:10.1007/s11940-012-0183-8. PMID 22622599.
- ↑ 2.0 2.1 2.2 Clinical Practice Guidelines in Oncology Central Nervous System Cancers. National Comprehensive Cancer Network.(2015) http://www.lecba-rakoviny.cz/dokumenty/NCCN_Guidelines_cns_2011.pdf Accessed on September,25 2015
- ↑ 3.0 3.1 Bartlett F, Kortmann R, Saran F (2013). “Medulloblastoma”. Clin Oncol (R Coll Radiol). 25 (1): 36–45. doi:10.1016/j.clon.2012.09.008. PMID 23245832.
- ↑ Medulloblastoma staging. Wikibooks(2015) https://en.wikibooks.org/wiki/Radiation_Oncology/Medulloblastoma/Staging Accessed on September, 28 2015)
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Haytham Allaham, M.D. [2]
